British pharmaceutical company Glaxosmithkline plc (GSK, GSK.LN) said on Wednesday that a phase III clinical trial of **** Healthcare has reached the main efficacy indicators. **** Healthcare is a joint shareholder of GlaxoSmithKline and Pfizer Inc. (PFE), which focuses on fighting HIV (HIV).

GlaxoSmithKline said the clinical trial showed that for patients who previously suppressed the virus using a three-drug regimen containing tenofovir alafenamide fumarate (tenofovir alafenamide fumarate), switching to a two-drug regimen with dolutegravir (dolutegravir) and lamivudine (lamivudine) can still inhibit HIV.

According to GlaxoSmithKline, the study was conducted to assess whether adults with HIV use at least three drug regimens including tenofovir and alafenamide and keep the virus suppressed for at least six months. Under such circumstances, they can switch to the two drug regimens described above and maintain the same virus suppression rate.

By Adria Calatayud; Write to Adria Calatayud at adria.calatayudvaello@dowjones.com


Copyright (c) 2019 Dow Jones Company. This article is copyrighted by Dow Jones, Inc., and may not be translated or reprinted without permission.